caffeine has been researched along with Coronary Artery Disease in 23 studies
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To explore the effect of acute caffeine ingestion on brachial artery flow-mediated dilation (FMD) in subjects without coronary artery disease (CAD; controls) and patients with CAD, we prospectively assessed brachial artery FMD in 40 controls and 40 age- and gender-matched patients with documented stable CAD on 2 separate mornings 1 week to 2 weeks apart." | 9.15 | Impact of acute caffeine ingestion on endothelial function in subjects with and without coronary artery disease. ( Chouraqui, P; Feinberg, MS; Harats, D; Koren-Morag, N; Scheinowitz, M; Sela, BA; Shalmon, G; Sharabi, Y; Shechter, M, 2011) |
| " The purpose of this study was to determine the effects of coffee intake <4 h prior to stress perfusion cardiac magnetic resonance imaging (CMR) in regadenoson- versus adenosine-induced hyperemia as measured with T1-mapping." | 7.85 | Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine-induced hyperemia as measured by T1 mapping. ( Kaandorp, TAM; Kuijpers, D; Oudkerk, M; van der Harst, P; van Dijk, R; van Dijkman, PRM; Vliegenthart, R, 2017) |
| "This multicenter, randomized, double-blind, placebo-controlled, parallel-group study includes patients with suspected coronary artery disease who regularly consume caffeine." | 5.15 | Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study. ( Franks, B; Iskandrian, AE; McNutt, BE; Tejani, FH; Thompson, RC, 2011) |
| " To explore the effect of acute caffeine ingestion on brachial artery flow-mediated dilation (FMD) in subjects without coronary artery disease (CAD; controls) and patients with CAD, we prospectively assessed brachial artery FMD in 40 controls and 40 age- and gender-matched patients with documented stable CAD on 2 separate mornings 1 week to 2 weeks apart." | 5.15 | Impact of acute caffeine ingestion on endothelial function in subjects with and without coronary artery disease. ( Chouraqui, P; Feinberg, MS; Harats, D; Koren-Morag, N; Scheinowitz, M; Sela, BA; Shalmon, G; Sharabi, Y; Shechter, M, 2011) |
| " The purpose of this study was to determine the effects of coffee intake <4 h prior to stress perfusion cardiac magnetic resonance imaging (CMR) in regadenoson- versus adenosine-induced hyperemia as measured with T1-mapping." | 3.85 | Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine-induced hyperemia as measured by T1 mapping. ( Kaandorp, TAM; Kuijpers, D; Oudkerk, M; van der Harst, P; van Dijk, R; van Dijkman, PRM; Vliegenthart, R, 2017) |
| "Myocardial perfusion scintigraphy (MPS) was used to assess adenosine-induced hyperemia in 30 patients before (baseline) and after coffee ingestion (caffeine)." | 3.74 | High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. ( Anagnostopoulos, C; Donovan, J; Harbinson, M; Loong, CY; Reyes, E; Underwood, SR, 2008) |
| " However, with its increasing popularity, numerous cases of adverse events related to synephrine use have been reported." | 3.01 | Review of Case Reports on Adverse Events Related to Pre-workout Supplements Containing Synephrine. ( de Jonge, MLL; Egberink, LB; Kieviet, LC; Sierts, M; van der Heyden, MAG, 2023) |
| "Caffeine intake was marginally inversely associated with coronary artery calcium progression." | 1.46 | Associations of Coffee, Tea, and Caffeine Intake with Coronary Artery Calcification and Cardiovascular Events. ( Averill, M; Blumenthal, RS; Burke, GL; Frazier-Wood, AC; Guallar, E; Lima, JAC; Martin, SS; Michos, ED; Miller, PE; Polak, JF; Post, WS; Sandfort, V; Zhao, D, 2017) |
| "Treatment with caffeine for 7 to 10 days in a mouse-model improved endothelial repair after denudation of the carotid artery." | 1.35 | Caffeine enhances endothelial repair by an AMPK-dependent mechanism. ( Dimmeler, S; Fichtlscherer, S; Fisslthaler, B; Haendeler, J; Liehn, EA; Popp, R; Spyridopoulos, I; Toennes, SW; Trepels, T; Weber, C; Zeiher, AM; Zernecke, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| de Jonge, MLL | 1 |
| Kieviet, LC | 1 |
| Sierts, M | 1 |
| Egberink, LB | 1 |
| van der Heyden, MAG | 1 |
| Yaghoobian, R | 1 |
| Sharifi, M | 1 |
| Rezaee, M | 1 |
| Vahidi, H | 1 |
| Salehi, N | 1 |
| Hosseini, K | 1 |
| Findley, AS | 1 |
| Richards, AL | 1 |
| Petrini, C | 1 |
| Alazizi, A | 1 |
| Doman, E | 1 |
| Shanku, AG | 1 |
| Davis, GO | 1 |
| Hauff, N | 1 |
| Sorokin, Y | 1 |
| Wen, X | 1 |
| Pique-Regi, R | 1 |
| Luca, F | 1 |
| van Assen, M | 1 |
| Kuijpers, DJ | 1 |
| Schwitter, J | 1 |
| Chong, JW | 1 |
| Lee, JC | 2 |
| Devaraj, SM | 1 |
| Miller, RG | 1 |
| Orchard, TJ | 1 |
| Kriska, AM | 1 |
| Gary-Webb, T | 1 |
| Costacou, T | 1 |
| van Dijk, R | 2 |
| Kuijpers, D | 2 |
| Kaandorp, TAM | 1 |
| van Dijkman, PRM | 1 |
| Vliegenthart, R | 1 |
| van der Harst, P | 2 |
| Oudkerk, M | 2 |
| Ties, D | 1 |
| Matangi, M | 1 |
| Dutchak, P | 1 |
| Einecke, D | 1 |
| Miller, PE | 1 |
| Zhao, D | 1 |
| Frazier-Wood, AC | 1 |
| Michos, ED | 1 |
| Averill, M | 1 |
| Sandfort, V | 1 |
| Burke, GL | 1 |
| Polak, JF | 1 |
| Lima, JAC | 1 |
| Post, WS | 1 |
| Blumenthal, RS | 1 |
| Guallar, E | 1 |
| Martin, SS | 1 |
| Spyridopoulos, I | 1 |
| Fichtlscherer, S | 1 |
| Popp, R | 1 |
| Toennes, SW | 1 |
| Fisslthaler, B | 1 |
| Trepels, T | 1 |
| Zernecke, A | 1 |
| Liehn, EA | 1 |
| Weber, C | 1 |
| Zeiher, AM | 1 |
| Dimmeler, S | 1 |
| Haendeler, J | 1 |
| Reyes, E | 1 |
| Loong, CY | 1 |
| Harbinson, M | 1 |
| Donovan, J | 1 |
| Anagnostopoulos, C | 1 |
| Underwood, SR | 1 |
| Vichayavilas, P | 1 |
| Kelly, C | 1 |
| Namdar, M | 1 |
| Schepis, T | 1 |
| Koepfli, P | 1 |
| Gaemperli, O | 1 |
| Siegrist, PT | 1 |
| Grathwohl, R | 1 |
| Valenta, I | 1 |
| Delaloye, R | 1 |
| Klainguti, M | 1 |
| Wyss, CA | 1 |
| Lüscher, TF | 1 |
| Kaufmann, PA | 1 |
| Reis, JP | 1 |
| Loria, CM | 1 |
| Steffen, LM | 1 |
| Zhou, X | 1 |
| van Horn, L | 1 |
| Siscovick, DS | 1 |
| Jacobs, DR | 1 |
| Carr, JJ | 1 |
| Tejani, FH | 1 |
| Thompson, RC | 1 |
| Iskandrian, AE | 3 |
| McNutt, BE | 1 |
| Franks, B | 1 |
| Shechter, M | 1 |
| Shalmon, G | 1 |
| Scheinowitz, M | 1 |
| Koren-Morag, N | 1 |
| Feinberg, MS | 1 |
| Harats, D | 1 |
| Sela, BA | 1 |
| Sharabi, Y | 1 |
| Chouraqui, P | 1 |
| Hage, FG | 1 |
| Fraser, JF | 1 |
| Barnett, AG | 1 |
| Johnson, LP | 1 |
| Wilson, MG | 1 |
| McHenry, CM | 1 |
| Walters, DL | 1 |
| Warnholtz, CR | 1 |
| Khafagi, FA | 1 |
| Yaylali, YT | 1 |
| Yaylali, O | 1 |
| Kirac, S | 1 |
| Aqel, RA | 1 |
| Zoghbi, GJ | 1 |
| Trimm, JR | 1 |
| Baldwin, SA | 1 |
| Lev, EI | 1 |
| Arikan, ME | 1 |
| Vaduganathan, M | 1 |
| Alviar, CL | 1 |
| Tellez, A | 1 |
| Mathuria, N | 1 |
| Builes, A | 1 |
| Granada, JF | 1 |
| del Conde, I | 1 |
| Kleiman, NS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Caffeine on Myocardial Oxygenation[NCT04585854] | 29 participants (Actual) | Interventional | 2020-11-13 | Completed | |||
| A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson[NCT00826280] | Phase 3 | 347 participants (Actual) | Interventional | 2009-03-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Baseline is the last non-missing measurement on or before first dose of regadenoson.~Change is calculated as the time point minus baseline." (NCT00826280)
Timeframe: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)
| Intervention | mmHg (Median) | |||
|---|---|---|---|---|
| Baseline [N= 113; 116;116] | Change at Day 5 (- 3 min) [N=67; 70; 71] | Change at Day 5 (+ 3 min) [N=67; 70; 72] | Change at Day 5 (+15 min) [N=66; 72; 72] | |
| Caffeine 200 mg Plus Regadenoson | 74.0 | 4.0 | 4.0 | 3.0 |
| Caffeine 400 mg Plus Regadenoson | 73.0 | 6.0 | 3.0 | 4.0 |
| Placebo Plus Regadenoson | 78.0 | 0.0 | -1.0 | -2.0 |
"Baseline is the last non-missing measurement on or before first dose of regadenoson~Change is calculated as the time point minus baseline." (NCT00826280)
Timeframe: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)
| Intervention | Beats per minute (Median) | |||
|---|---|---|---|---|
| Baseline [N=113; 116; 116] | Change at Day 5 (- 3 min) [N=67; 70; 71] | Change at Day 5 (+3 min) [N=67; 70; 72] | Change at Day 5 (+15 min) [N=66; 72; 72] | |
| Caffeine 200 mg Plus Regadenoson | 62.0 | -1.0 | 5.0 | 1.0 |
| Caffeine 400 mg Plus Regadenoson | 64.0 | -2.0 | 0.0 | -1.0 |
| Placebo Plus Regadenoson | 66.0 | -2.0 | 9.0 | 4.0 |
"Baseline is the last non-missing measurement on or before first dose of regadenoson.~Change is calculated as the time point minus baseline." (NCT00826280)
Timeframe: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)
| Intervention | mmHg (Median) | |||
|---|---|---|---|---|
| Baseline [N=113; 116; 116] | Change at Day 5 (- 3 min) [N=67;70;71] | Change at Day 5 (+3 min) [N=67; 70; 72] | Change at Day 5 (+15 min) [N=66; 72; 72] | |
| Caffeine 200 mg Plus Regadenoson | 131.0 | 12.0 | 8.0 | 8.0 |
| Caffeine 400 mg Plus Regadenoson | 135.0 | 11.0 | 7.5 | 5.0 |
| Placebo Plus Regadenoson | 135.0 | 0.0 | 0.0 | -2.0 |
"Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.~Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3)." (NCT00826280)
Timeframe: Day 3 and Day 5
| Intervention | Reversible Defects (Mean) | ||
|---|---|---|---|
| Baseline Stress Scan (Day 3) | Double-Blind Stress Scan (Day 5) | DoubleBlind - Baseline (Day 5 - Day 3) | |
| Caffeine 200 mg Plus Regadenoson | 1.01 | 0.40 | -0.61 |
| Caffeine 400 mg Plus Regadenoson | 1.00 | 0.38 | -0.62 |
| Placebo Plus Regadenoson | 0.67 | 0.80 | 0.12 |
"Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.~Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3)." (NCT00826280)
Timeframe: Day 3 and Day 5
| Intervention | Reversible Defects (Mean) | ||
|---|---|---|---|
| Baseline Stress Scan (Day 3) [N=64; 69; 70] | Double-Blind Stress Scan (Day 5) [N=66; 70; 71] | DoubleBlind - Baseline (Day 5-Day 3)[N=64; 69; 70] | |
| Caffeine 200 mg Plus Regadenoson | 2.00 | 1.46 | -0.59 |
| Caffeine 400 mg Plus Regadenoson | 2.19 | 1.42 | -0.81 |
| Placebo Plus Regadenoson | 1.47 | 1.74 | 0.31 |
"The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).~Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).~The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD)." (NCT00826280)
Timeframe: Day 3 and Day 5
| Intervention | Sum Difference Score (Mean) | ||
|---|---|---|---|
| Baseline Stress Scan (Day 3) | Double-Blind Stress Scan (Day 5) | DoubleBlind - Baseline (Day 5 - Day 3) | |
| Caffeine 200 mg Plus Regadenoson | 2.45 | 1.42 | -1.03 |
| Caffeine 400 mg Plus Regadenoson | 2.53 | 1.27 | -1.25 |
| Placebo Plus Regadenoson | 2.24 | 2.36 | 0.11 |
"The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).~Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).~The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD)." (NCT00826280)
Timeframe: Day 3 and Day 5
| Intervention | Summed Difference Score (Mean) | ||
|---|---|---|---|
| Baseline Stress Scan (Day 3) [N=64; 69; 70] | Double-Blind Stress Scan (Day 5) [N=66; 70; 71] | DoubleBlind - Baseline (Day 5-Day 3)[N=64; 69; 70] | |
| Caffeine 200 mg Plus Regadenoson | 4.46 | 3.10 | -1.45 |
| Caffeine 400 mg Plus Regadenoson | 4.29 | 2.46 | -1.84 |
| Placebo Plus Regadenoson | 3.34 | 4.41 | 1.02 |
4 reviews available for caffeine and Coronary Artery Disease
| Article | Year |
|---|---|
Review of Case Reports on Adverse Events Related to Pre-workout Supplements Containing Synephrine.
Topics: Caffeine; Coronary Artery Disease; Dietary Supplements; Humans; Synephrine | 2023 |
Caffeine Drug Interactions and its Clinical Implication After Acute Coronary Syndrome: A Literature Review.
Topics: Acute Coronary Syndrome; Caffeine; Coffee; Coronary Artery Disease; Drug Interactions; Humans | 2023 |
MRI perfusion in patients with stable chest-pain.
Topics: Artifacts; Caffeine; Central Nervous System Stimulants; Chest Pain; Coronary Angiography; Coronary A | 2020 |
Effects of Caffeine on Myocardial Blood Flow: A Systematic Review.
Topics: Adult; Aged; Caffeine; Clinical Decision-Making; Coronary Artery Disease; Coronary Circulation; Fema | 2018 |
6 trials available for caffeine and Coronary Artery Disease
| Article | Year |
|---|---|
Buccal caffeine for the routine reversal of Persantine.
Topics: Administration, Buccal; Aged; Caffeine; Coronary Artery Disease; Dipyridamole; Exercise Test; Female | 2014 |
Caffeine impairs myocardial blood flow response to physical exercise in patients with coronary artery disease as well as in age-matched controls.
Topics: Aging; Caffeine; Case-Control Studies; Coronary Artery Disease; Coronary Circulation; Exercise; Fema | 2009 |
Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Adult; Aged; Aged, 80 and over; Caffeine; C | 2011 |
Impact of acute caffeine ingestion on endothelial function in subjects with and without coronary artery disease.
Topics: Biomarkers; Brachial Artery; Caffeine; Case-Control Studies; Coronary Artery Disease; Double-Blind M | 2011 |
Effect of caffeine on adenosine-induced reversible perfusion defects assessed by automated analysis.
Topics: Adenosine; Blood Flow Velocity; Caffeine; Coronary Artery Disease; Coronary Circulation; Drug Intera | 2012 |
Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Adult; Caffeine; Coronary Artery Disease; Hemodynamics | 2004 |
13 other studies available for caffeine and Coronary Artery Disease
| Article | Year |
|---|---|
Interpreting Coronary Artery Disease Risk Through Gene-Environment Interactions in Gene Regulation.
Topics: Caffeine; Coronary Artery Disease; Endothelial Cells; Gene Expression Regulation; Gene-Environment I | 2019 |
The impact of caffeine ingestion on different assessment modalities for myocardial ischaemia.
Topics: Caffeine; Coronary Artery Disease; Eating; Humans; Myocardial Ischemia | 2021 |
Data driven patterns of nutrient intake and coronary artery disease risk in adults with type 1 diabetes.
Topics: Adolescent; Adult; Caffeine; Child; Coronary Artery Disease; Diabetes Mellitus, Type 1; Eating; Ener | 2021 |
Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine-induced hyperemia as measured by T1 mapping.
Topics: Adenosine; Aged; Caffeine; Coffee; Coronary Artery Disease; Coronary Circulation; Female; Humans; Hy | 2017 |
[Coronary calcium deposits caused by cola drinking?].
Topics: Adult; Caffeine; Carbonated Beverages; Coronary Artery Disease; Health Surveys; Humans; Republic of | 2016 |
Associations of Coffee, Tea, and Caffeine Intake with Coronary Artery Calcification and Cardiovascular Events.
Topics: Aged; Caffeine; Cardiovascular Diseases; Coffee; Coronary Artery Disease; Female; Humans; Male; Midd | 2017 |
Caffeine enhances endothelial repair by an AMPK-dependent mechanism.
Topics: Adenosine Triphosphate; Adult; AMP-Activated Protein Kinases; Animals; Bone Marrow Transplantation; | 2008 |
High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine.
Topics: Adenosine; Aged; Caffeine; Central Nervous System Stimulants; Coffee; Coronary Artery Disease; Coron | 2008 |
Relationship between sleep duration and incident coronary artery calcification.
Topics: Caffeine; Calcinosis; Coffee; Coronary Artery Disease; Humans; Sleep | 2009 |
Coffee, decaffeinated coffee, caffeine, and tea consumption in young adulthood and atherosclerosis later in life: the CARDIA study.
Topics: Adolescent; Adult; Caffeine; Carotid Arteries; Coffee; Cohort Studies; Coronary Artery Disease; Fema | 2010 |
The effect of caffeine on adenosine myocardial perfusion imaging: time to reassess?
Topics: Adenosine; Caffeine; Coronary Artery Disease; Coronary Circulation; Exercise Test; Female; Humans; M | 2012 |
Impact of caffeine ingestion on ventricular function in coronary artery disease.
Topics: Aged; Caffeine; Coffee; Coronary Artery Disease; Echocardiography, Doppler; Female; Humans; Male; Mi | 2013 |
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease.
Topics: Adult; Aged; Caffeine; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Drug Synergism; Fem | 2007 |